Sam Fazeli

And today I'm very happy to say that we have Susan Goldbraith from AstraZeneca again.

And now after the ESMO, the European Society for Medical Oncology Conference, to discuss some of the data.

And of course, again, AstraZeneca was one of the leading companies at the conference in terms of key data sets being reported.

And we did one after ASCO, which went really well.

And I really appreciate the time that Susan offers us.

Susan, of course, everybody knows, Executive Vice President of Oncology R&D at AstraZeneca, which is, if not the leading, one of the top leading oncology plays in the pharmaceutical sector.

So Susan, just before we start, I wondered if you wanted to say any introductory words or we can go straight to first question on breast cancer.

So that's a perfect lead into our first conversation, talking about early intervention with an ADC.

And that's, of course, the data they presented in breast cancer.

Now, just for setting the scene, because we have a whole variety of folks who listen to this podcast, from super experts to more generalists, just to be setting the scene here, breast cancer comes in

I would say, if that's fair enough, Susan, I don't know whether you agree, three main forms.

Hormone receptor positive, HER2 positive, and then, of course, triple negative breast cancer.

Do you agree with that?

Okay.

So you had some very interesting and exciting data at ESMO in the HER2 positive space.

And these are patients who have an alteration in either the expression or mutations in their HER2 gene, which whoever wants to can go on Google and find out about it.

So you had Destiny Breast 11 and Destiny Breast 05, both testing in two different settings.

And HER2, which is the HER2 ADC that you have as partnered with Daiichi Sankyo.

So maybe you want to talk us through that.

You have a big segment of this population in terms of patients covered.